Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT03284853
Other study ID # PG324-CS303
Secondary ID
Status Completed
Phase Phase 3
First received
Last updated
Start date September 5, 2017
Est. completion date November 6, 2020

Study information

Verified date January 2022
Source Aerie Pharmaceuticals
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

The study is intended to test the effectiveness and safety of Netarsudil / Latanoprost 0.02% / 0.005% Ophthalmic Solution, relative to GANFORT® for lowering of intraocular pressure (IOP) in patients with elevated intraocular pressure


Recruitment information / eligibility

Status Completed
Enrollment 436
Est. completion date November 6, 2020
Est. primary completion date November 6, 2020
Accepts healthy volunteers No
Gender All
Age group 18 Years and older
Eligibility Inclusion Criteria: 1. Must be 18 years of age or older. 2. Diagnosis of OAG or OHT in both eyes (OAG in one eye and OHT in the fellow eye is acceptable). 3. Subjects insufficiently controlled and/or subjects considered in need for combination therapy by the investigators. 4. Medicated intraocular pressure = 17 mmHg in at least one eye and < 28mmHg in both eyes at screening visit. 5. Unmedicated (post-washout) IOP >20mmHg in at least one eye and < 36mmHg in both eyes at 2 qualification visits at 08:00 hour, 2-7 days apart. At the second qualification visit, have IOP >17mmHg in at least one eye and < 36mmHg in both eyes at 10:00 and 16:00 hours. Note: For purposes of determining eligibility of subjects to be enrolled, the non-integral IOP mean number will be used. Any non-integral mean IOP number should not be rounded. If only one eye qualifies at the second qualification visit it MUST be the same eye that qualified on the first visit and this will be the study eye for the duration of the study. 6. Best corrected visual acuity +1.0 logMAR or better by ETDRS in each eye (equivalent to 20/200 or better Snellen visual acuity in each eye). 7. Be able and willing to give signed informed consent and follow study instruction. 8. Women must be either of non-childbearing potential, or women with childbearing potential and men with reproductive potential must be willing to practice acceptable methods of birth control during the study. 9. Women of childbearing potential must have a negative urine pregnancy test within 7 days of first dose of study treatment and agree to use highly effective contraception during the study and for 3 months after the last dose of study medication. 10. Men with a female partner of childbearing potential must have either had a prior vasectomy or agree to use an effective form of contraception from time of randomization and for 3 months following the last dose of study medication. 11. In France, a subject will be eligible for inclusion in this study only if either affiliated to or as a beneficiary of a social security number. Exclusion Criteria: Ophthalmic: 1. Clinically significant ocular disease (e.g., corneal edema, uveitis, or severe keratoconjunctivitis sicca) which might interfere with interpretation of the study efficacy endpoints or with safety assessments, including subjects with glaucomatous damage so severe that washout of ocular hypotensive medications for 4 weeks or longer if needed is not judged safe as it would put the subject at risk for further vision loss. 2. Pseudoexfoliation or pigment dispersion component glaucoma, history of angle closure glaucoma, or narrow angles i.e. Grade 2 Shaffer (Chan 1981) or less extreme narrow angle with complete or partial closure. Note: Previous laser peripheral iridotomy is NOT acceptable. 3. Intraocular pressure = 36mmHg (unmedicated) in either eye (individuals who are excluded for this criterion are not allowed to attempt requalification), or use of more than two ocular hypotensive medications within 30 days of screening. Note: fixed dose combination medications, for the purpose of this exclusion criterion, count as one medication. However, subjects currently taking 2 fixed dose combination products are excluded. 4. Treatment-naïve subjects. 5. Prior treatment with GANFORT® topical eye drops where the subjects IOP did not achieve the target IOP and was considered either a therapeutic failure or to have insufficient response. Subjects currently (immediately prior to screening visit) being treated with GANFORT® are excluded from the study. 6. Known hypersensitivity to any component of the investigational formulations to be used (e.g., benzalkonium chloride) or to fluorescein. 7. Previous glaucoma intraocular surgery, including SLT or ALT in either eye. 8. Refractive surgery in either eye (e.g., radial keratotomy, PRK, LASIK, corneal cross-linking, keratoplasty). 9. Ocular trauma within the six months prior to screening, or ocular surgery or non-refractive laser treatment within the three months prior to screening. 10. Recent or current evidence of ocular infection or inflammation in either eye. Current evidence of clinically significant blepharitis, conjunctivitis, keratitis, current evidence or history of herpes simplex or zoster keratitis in either eye at screening. 11. Use of ocular medication in either eye of any kind within 30 days of screening and throughout the study, with the exception of a) ocular hypotensive medications which must have been the same medication for 30 days prior to screening (which must be washed out according to the provided schedule), b) lid scrubs (which may be used prior to, but not after, screening), c) lubricating drops for dry eye (which may be used throughout the study), as prescribed by the Investigator. 12. Mean central corneal thickness greater than 620µm at screening. 13. Any abnormality preventing reliable Goldmann applanation tonometry of either eye (e.g., keratoconus). Systemic: 14. Clinically significant abnormalities in laboratory tests at screening. 15. Known hypersensitivity or contraindication to GANFORT® (Appendix 3 Marketed Product Medication Information Section 4.3) and to ß-adrenoceptor antagonists (e.g. Chronic obstructive pulmonary disease or bronchial asthma; abnormally low blood pressure or heart rate; second or third-degree heart block or congestive heart failure, cardiac failure, cardiac shock and severe diabetes). 16. Clinically significant systemic disease which might interfere with the study. 17. Participation in any investigational study within 30 days prior to screening. 18. Systemic medication including corticosteroid containing drugs that could have a substantial effect on IOP which HAVE NOT been maintained at a consistent dose and regime within 30 days prior to screening, and are anticipated to change in dose and/or regime during the study. 19. Use of topical steroid containing medications on the face or in or around the eyes will exclude the subject (see Section 5.6 Concomitant Medications). 20. Women of childbearing potential who are pregnant, nursing, planning a pregnancy, or not using a medically acceptable and highly effective form of birth control. An adult woman is considered to be of childbearing potential unless she is one year post-menopausal (1 year without menses with appropriate clinical profile, e.g. age appropriate, > 45 years in the absence of HRT. In questionable cases the subject must have FSH value > 40mIU/mL and an estradiol value < 40pg/mL (< 140pmol/L)) or three months post-surgical sterilization. 21. Vulnerable subjects such as minors, adults under legal protection or unable to express their consent (e.g. hospitalized persons in coma), persons deprived of liberty (prisoners from jails), or persons subject to psychiatric care.

Study Design


Intervention

Drug:
Netarsudil/Latanoprost 0.02%/0.005%
Topical sterile ophthalmic solution
GANFORT®
Topical sterile ophthalmic solution

Locations

Country Name City State
Austria State Hospital - University Medical Center Academical Department of Ophthalmology Graz
Austria Albertgasse 39/10+11 Vienna
Austria Hanusch Hospital Vienna
Belgium UZ Leuven, campus Gasthuisberg, Herestraat 49, 3000 Leuven Leuven
Czechia Faculty Hospital Brno Eye Department Brno
Czechia Glaucoma center Ocní klinika VFN a 1. LF UK Praha
France Ophthalmology Service Centre Francois Xavier Michelet CHU Pellegrin Bordeaux
France Centre ophtalmologique Pole vision val d'ouest Ecully
France Ophthalmology Service - Batiment R Hospital de la Croix-Rousse Lyon
France CHU de Nantes-Hospital Hotel Dieu Ophthalmology Service Nantes
France Ophthalmology department Necker University Hospital-Enfants Malades Paris
Germany University Medical Center Freiburg, Eye Center,Killianstr.5, Freiburg i. Breisgau Freiburg
Germany Department of Ophthalmology Clinical Johannes Gutenberg-University Mainz Mainz
Germany Universitats-Augenklinik, Studienzentrum/Clinical Trials in Opthalmology (CTO) Münster
Germany University Eye Hospital Tuebingen, STC eyetrial at the center for Ophthalmolgy Tuebingen
Germany Augenarztpraxis Dr. Andreas Bayer Weilheim
Hungary Budapest Retina Associates Budapest
Hungary Department of Ophthalmology Semmelweis University Budapest
Hungary University of Debrecen, Clinical Center, Ophthalmology Department Debrecen
Hungary Clinexpert Gyongyos Kft. Heves
Hungary Ganglion Medical Center Pécs
Hungary University of Szeged, Department of Ophthalmology Szeged
Hungary Markusovszky University Teaching Hospital Szombathely
Italy Ophthalmic Clinic DiNOGMI University Hospital San Martino Genova
Italy ASST Fatebenefratelli Sacco P.O.L.Sacco Milan
Italy ASST Santi Paolo e Carlo - Ophthalmic Clinic Milan
Italy Dept. Ophthalmology, San Raffaele Hospital Milano
Italy Department of Medicine and Surgery University of Parma Parma
Italy Ophthamic Clinic of the University of Pavia, IRCCS Foundation San Matteo Policlinic Pavia
Italy AOU Pisana Hospital of Cisanello Pisa
Italy G.B.Bietti Foundation - IRCCS Rome
Italy Senese University Hospital Siena
Italy S.C.U Oculistica, Azienda Ospedaliero Universitaria, Città della Salute e della Scienza Torino
Italy University Eye Clinic Ospedale Maggiore Trieste
Italy Politecnico Gianbattista Rossi AOUI Ospedale Borgo Roma Verona
Latvia Signes Ozolinas Doctor Practice in Ophthalmology Jelgava
Latvia Latvian American Eye Centre (LAAC) Riga
Latvia P.Stradins Clinical University Hospital, Ophthalmology Clinic Riga
Latvia Riga East University hospital, In-patient Department "Bikernieki", Ophthalmology Clinic Riga
Poland Professor K. Gibinski University Clinical Centre Katowice
Poland Ophthalmic Clinic Jasne Blonia Lódz
Poland Department of Diagnostics and Microsurgery of Glaucoma Lublin
Poland Military Institute of Medicine Klinika Okulistyki Warsaw
Spain Centro de Oftalmologia Barraquer Barcelona
Spain Hospital General de Catalunya Ophthalmology Department Barcelona
Spain Hospital QuironSalud Barcelona Barcelona
Spain Institut Catala de retina (ICR) Glaucoma and Investigation Department Barcelona
Spain Hospital General del S.A.S. de Jerez de la Frontera Cádiz
Spain Hospital Universitario Reina Sofía de Córdoba Córdoba
Spain Centro de Ojos de la Coruña La Coruña
Spain Hospital Universitario Virgen Macarena Ophthalmology Department Sevilla
Spain Hospital Universitario de Torrevieja Ophthalmology Department Torrevieja
Spain FISABIO-Oftalmología Médica Valencia
Spain Ophthalmology Department Hospital Universitario Rio Hortega Valladolid
Spain Hospital Clinico Universitario Lozano Blesa Zaragoza Ophthalmology department Zaragoza
Spain Hospital Universitario Miguel Servet Ophthalmology Department Zaragoza
United Kingdom NHS Grampian Aberdeen Royal Infirmary Aberdeen
United Kingdom Cambridge University Hospitals NHS Trust Cambridge
United Kingdom Ophthalmology Department, Queen Alexandra Hospital Cosham
United Kingdom Mid-Cheshire Hospitals NHS Foundation Trust Crewe
United Kingdom Northwest Anglia NHS Foundation trust Hinchingbrooke Hospital Huntingdon
United Kingdom Guy's & St Thomas' NHS Foundation Trust Glaucoma Research Area London
United Kingdom King's College Hospital London
United Kingdom Moorfields Eye Hospital NHS London
United Kingdom Western Eye Hospital London
United Kingdom Royal Hallamshire Hospital Sheffield
United Kingdom Queen Mary Hospital, King's College Hospital NHS Sidcup
United Kingdom City Hospitals Sunderland NHS Foundation Trust Sunderland Eye Infirmary Sunderland Tyne And Wear

Sponsors (1)

Lead Sponsor Collaborator
Aerie Pharmaceuticals

Countries where clinical trial is conducted

Austria,  Belgium,  Czechia,  France,  Germany,  Hungary,  Italy,  Latvia,  Poland,  Spain,  United Kingdom, 

Outcome

Type Measure Description Time frame Safety issue
Primary Mean Diurnal Intraocular Pressure by Goldmann Applanation Tonometry Comparison of PG324 to Ganfort for mean intraocular pressure at specified timepoints at Week 2, Week 6 and Month 3. Day 90
See also
  Status Clinical Trial Phase
Completed NCT01157364 - Safety and Efficacy of a New Ophthalmic Formulation of Bimatoprost in Patients With Open Angle Glaucoma and Ocular Hypertension Phase 1/Phase 2
Not yet recruiting NCT06441643 - Next Generation Rocklatan Phase 2
Recruiting NCT02792803 - A Comparison of Xalatan (Latanoprost) to Apo-latanoprost and Co-latanoprost in the Treatment of Glaucoma Phase 4
Recruiting NCT02471105 - Investigation of IOP and Tolerability of Bimatoprost 0.01% and Tafluprost Unit Dose Preservative Free 15 Microgram/ml Phase 4
Completed NCT02558374 - Double-masked Study of Netarsudil (AR-13324) Ophthalmic Solution in Subjects With Glaucoma or Ocular Hypertension Phase 3
Terminated NCT02801617 - Non-inferiority of PRO-067 Ophthalmic Solution vs GAAP Ofteno® in Glaucoma or Ocular Hypertension Phase 3
Completed NCT02246764 - Study of Netarsudil (AR-13324) Ophthalmic Solution in Patients With Glaucoma or Ocular Hypertension Phase 3
Completed NCT02993445 - Effect of Alternate Therapies on Intraocular Pressure in Ocular Hypertension N/A
Completed NCT02390245 - Philadelphia Telemedicine Glaucoma Detection and Follow-Up Study N/A
Completed NCT02628223 - 180 Degree vs. 360 Degree Selective Laser Trabeculoplasty as Initial Therapy for Glaucoma N/A
Completed NCT02338362 - Inhaled Corticosteroids: Effect on Intraocular Pressure in Patients With Controlled Glaucoma Phase 4
Completed NCT02003547 - A Single Centre Study to Evaluate 3 Ophthalmic Formulations in Healthy Subjects Phase 1
Completed NCT01936389 - A Prospective Study to Assess the Hypotensive Efficacy of Rho-Kinase Inhibitor AR-12286 Ophthalmic Solution 0.5% and 0.7% in Patients With Exfoliation Syndrome and Ocular Hypertension or Glaucoma Phase 2
Completed NCT01995136 - Investigation of Intraocular Pressure (IOP) Reduction Efficacy of Travoprost Ophthalmic Solution in Patients With Normal Tension Glaucoma Phase 4
Completed NCT01693315 - Multiple Dose-escalation Study of AMA0076 in Patients With Ocular Hypertension or Primary Open-angle Glaucoma Phase 2
Completed NCT01664039 - An Efficacy and Tolerability Study of TRAVATAN® Versus LUMIGAN® Phase 4
Active, not recruiting NCT01430923 - Clinical Evaluation of Safety and Efficacy of Refrigeration Free Latanoprost N/A
Completed NCT01426867 - A Comfort Study of Brinzolamide 1% / Brimonidine 0.2% Fixed Combination, Brinzolamide 1% and Brimonidine 0.2% Phase 2
Completed NCT01340014 - Patient Preference Comparison of AZARGA Versus COSOPT Phase 4
Completed NCT01489670 - Observational Study of Lumigan® 0.01% Treatment for Patients With Primary Open Angle Glaucoma or Ocular Hypertension N/A